Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells

Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults. Due to its heterogeneity, the abundance of altered signaling pathways within the same tumoral mass, its low immunogenicity, and the presence of the blood–brain barrier, standard therapies based on surgical resection, radio...

Full description

Saved in:
Bibliographic Details
Main Authors: Claudio Casali, Ludovica Gaiaschi, Enrico Pelloni, Federica Gola, Margherita Cavallo, Gloria Milanesi, Mauro Ravera, Marco Biggiogera, Fabrizio De Luca, Maria Grazia Bottone
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1506206/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850235037317857280
author Claudio Casali
Ludovica Gaiaschi
Enrico Pelloni
Federica Gola
Margherita Cavallo
Gloria Milanesi
Mauro Ravera
Marco Biggiogera
Fabrizio De Luca
Maria Grazia Bottone
author_facet Claudio Casali
Ludovica Gaiaschi
Enrico Pelloni
Federica Gola
Margherita Cavallo
Gloria Milanesi
Mauro Ravera
Marco Biggiogera
Fabrizio De Luca
Maria Grazia Bottone
author_sort Claudio Casali
collection DOAJ
description Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults. Due to its heterogeneity, the abundance of altered signaling pathways within the same tumoral mass, its low immunogenicity, and the presence of the blood–brain barrier, standard therapies based on surgical resection, radiotherapy, and chemotherapy result in ineffective tumor removal. For these reasons, the development of new drugs is mandatory to ameliorate patients’ life expectancy and quality of life. Cathepsins are lysosomal proteases involved in several physiological and pathological processes, and they play key roles in modulating cell death and pharmacological resistance. In particular, cathepsin B is a crucial regulatory protein in different types of cell death, and its overexpression contributes to GBM angiogenesis and tumor progression. Octahedral platinum(IV) (Pt(IV))-based prodrugs have already demonstrated improved anticancer efficacy compared to routinely used cisplatin. This work aims to investigate the effects of two such prodrugs—Pt(IV)Ac-POA ((OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(IV)) and DB178 ((OC-6-44)-acetatodiamminedichlorido(4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylato)platinum(IV))—on two different glioblastoma cell lines, U251 and T98G, with particular attention to their effects on cathepsin B. The immunocytochemical and biochemical results obtained on the two cell lines highlight the maintenance of basal levels of cathepsin B while efficiently activating programmed cell death mechanisms, as investigated by optical and electronic microscopy. These findings may serve as a valid starting point for further approaches that incorporate cathepsins’ inhibitors to improve therapeutic efficacy and possibly reveal novel pharmacological targets.
format Article
id doaj-art-529f8d3ff3b84df5b40af32f961527b7
institution OA Journals
issn 2296-634X
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj-art-529f8d3ff3b84df5b40af32f961527b72025-08-20T02:02:26ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-06-011310.3389/fcell.2025.15062061506206Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cellsClaudio Casali0Ludovica Gaiaschi1Enrico Pelloni2Federica Gola3Margherita Cavallo4Gloria Milanesi5Mauro Ravera6Marco Biggiogera7Fabrizio De Luca8Maria Grazia Bottone9Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyDepartment of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale “A. Avogadro”, Alessandria, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyLaboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, ItalyGlioblastoma (GBM) is the most frequent and aggressive brain tumor in adults. Due to its heterogeneity, the abundance of altered signaling pathways within the same tumoral mass, its low immunogenicity, and the presence of the blood–brain barrier, standard therapies based on surgical resection, radiotherapy, and chemotherapy result in ineffective tumor removal. For these reasons, the development of new drugs is mandatory to ameliorate patients’ life expectancy and quality of life. Cathepsins are lysosomal proteases involved in several physiological and pathological processes, and they play key roles in modulating cell death and pharmacological resistance. In particular, cathepsin B is a crucial regulatory protein in different types of cell death, and its overexpression contributes to GBM angiogenesis and tumor progression. Octahedral platinum(IV) (Pt(IV))-based prodrugs have already demonstrated improved anticancer efficacy compared to routinely used cisplatin. This work aims to investigate the effects of two such prodrugs—Pt(IV)Ac-POA ((OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(IV)) and DB178 ((OC-6-44)-acetatodiamminedichlorido(4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylato)platinum(IV))—on two different glioblastoma cell lines, U251 and T98G, with particular attention to their effects on cathepsin B. The immunocytochemical and biochemical results obtained on the two cell lines highlight the maintenance of basal levels of cathepsin B while efficiently activating programmed cell death mechanisms, as investigated by optical and electronic microscopy. These findings may serve as a valid starting point for further approaches that incorporate cathepsins’ inhibitors to improve therapeutic efficacy and possibly reveal novel pharmacological targets.https://www.frontiersin.org/articles/10.3389/fcell.2025.1506206/fullglioblastomacathepsin Bdrug resistanceplatinum(IV)apoptosismitophagy
spellingShingle Claudio Casali
Ludovica Gaiaschi
Enrico Pelloni
Federica Gola
Margherita Cavallo
Gloria Milanesi
Mauro Ravera
Marco Biggiogera
Fabrizio De Luca
Maria Grazia Bottone
Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
Frontiers in Cell and Developmental Biology
glioblastoma
cathepsin B
drug resistance
platinum(IV)
apoptosis
mitophagy
title Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
title_full Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
title_fullStr Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
title_full_unstemmed Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
title_short Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells
title_sort platinum iv anticancer therapies and cathepsin b innovative strategies for overcoming resistance in glioblastoma cells
topic glioblastoma
cathepsin B
drug resistance
platinum(IV)
apoptosis
mitophagy
url https://www.frontiersin.org/articles/10.3389/fcell.2025.1506206/full
work_keys_str_mv AT claudiocasali platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT ludovicagaiaschi platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT enricopelloni platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT federicagola platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT margheritacavallo platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT gloriamilanesi platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT mauroravera platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT marcobiggiogera platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT fabriziodeluca platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells
AT mariagraziabottone platinumivanticancertherapiesandcathepsinbinnovativestrategiesforovercomingresistanceinglioblastomacells